MedTrace Logo

AssesSment of Early deteCtion basEd oN liquiD Biopsy in Intracranial Tumors

NCT05679089 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 358

Last updated 2023-01-10

No results posted yet for this study

Summary

ASCEND-BRAIN is a prospective, observational study aimed at early-detection of intracranial tumors by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 358 participants including intracranial malignant tumors, patients with benign disorders of central nervous system and healthy participants.

Conditions

  • Intracranial Tumors

Interventions

DEVICE

early detection test

Blood collection and early detection testing

Sponsors & Collaborators

  • Guangzhou Burning Rock Dx Co., Ltd.

    collaborator INDUSTRY

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Hongbo Guo, MD,Ph.D · Zhujiang Hospital

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-12-31
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05679089 on ClinicalTrials.gov